Background: Angiogenesis, required for all tumor growth, is stimulated by the expression of vascular endothelial growth factor (VEGF). VEGF is up-regulated in all known solid tumors but also in atherosclerosis, diabetic retinopathy, arthritis, and many other conditions. Conventional VEGF isoforms have been universally described as proangiogenic cytokines. VEGF 165b, an endogenous splice variant, is expressed as protein in normal cells and tissues and is circulating in human plasma. VEGF 165b binds VEGF receptor 2 with the same affinity as VEGF 165 but does not activate it or stimulate downstream signaling pathways. Moreover, it prevents VEGF 165-mediated VEGF receptor 2 phosphorylation and signaling in cultured cells. VEGF 165b is not angiogenic and it inhibits VEGF 165-mediated angiogenesis in rabbit cornea and rat mesentery.
Description: Rabbit polyclonal to VEGF165B
Immunogen: KLH conjugated synthetic peptide derived from VEGF165B
Specificity: ·Reacts with Human, Mouse and Rat.
.·Isotype: IgG
Application: ·Western blotting: 1/100-500. Predicted Mol wt: 27 kDa;
·Immunohistochemistry (Paraffin/frozen tissue section): 1/50-200;
·Immunocytochemistry/Immunofluorescence: 1/100;
·Immunoprecipitation: 1/50;
·ELISA: 1/500;
·Optimal working dilutions must be determined by the end user.
